Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

By V. Bronte, S. Brandau, Shu-Hsia Chen, M. Colombo, A. Frey, T. Greten, S. Mandruzzato, P. Murray, Augusto Ochoa, S. Ostrand-Rosenberg and 5 more. Nature Communications, 2016

2,457 citations recorded by the source corpus.

Myeloid-derived suppressor cells (MDSC) are a heterogeneous population expanded in cancer and other chronic inflammatory conditions. Here the authors identify the challenges and propose a set of minimal reporting guidelines for mouse and human MDSC. Myeloid-derived suppressor cells (MDSCs) have emerged as major regulators of immune responses in cancer and other pathological conditions. In recent years, ample evidence supports key contributions of MDSC to tumour progression through both immune-mediated mechanisms and those not directly associated with immune suppression. MDSC are the subject of intensive research with >500 papers published in 2015 alone. However, the phenotypic, morphological and functional heterogeneity of these cells generates confusion in investigation and analysis of their roles in inflammatory responses. The purpose of this communication is to suggest characterization standards in the burgeoning field of MDSC research.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/6609ec54a05d89aa536fe6771ccd5cad6dfa3f5e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Mildner
2. R. DePinho
3. Guocan Wang
4. Di Zhao
5. D. Spring
6. D. Gabrilovich
7. A. Aschenbrenner
8. Oliver Stegle

Citations in the corpus

• Developmental and Functional Heterogeneity of Monocytes. (2018, background): “Addition of further cell surface markers unmasked the presence of monocytic and polymorphonuclear MDSC and allowed independent analysis of both subsets (Bronte et al., 2016; Gallina et al., 2006; Huang et al., 2006; Movahedi et al., 2008).”
• Genetics and biology of prostate cancer (2018, background): “Human MDSCs express markers such as CD11b and CD33 but are mostly negative for human leukocyte antigen–antigen D-related and lineage-specific antigens, including CD3, CD19, and CD57 (Gabrilovich et al. 2012; Bronte et al. 2016), and can be separated into PMN-MDSCs and M-MDSCs (Table 2).”
• Myeloid-derived suppressor cells (2017, background): “The term "early-stage MDSC" (e-MDSC) has been proposed for this latter population (7).”
• The Tumor Microenvironment Innately Modulates Cancer Progression (2019, background): “eMDSCs Suppress innate and adaptive immune responses N/A CD33þ, Lin , CD13 , CD14 CD3 , CD6 Not well characterized Protumor (42)”
• Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment (2020, positive): “In contrast, in severe COVID-19, monocytes showed low expression of HLADR, and high levels of MAFB, PLBD1, and CD163, all of which are associated with anti-inflammatory macrophage functions (Bronte et al., 2016; Cuevas et al., 2017; Fischer-Riepe et al., 2020; MacParland et al., 2018).”